News & Events

W. L. Gore & Associates, Inc. (Gore) announced the acquisition of InnAVasc Medical, Inc., a privately held medical technology company focused on advancing care for patients with end stage renal disease who utilize graft circuits for dialysis treatment.

W.L. Gore & Associates, Inc. continues to build on its growing portfolio of protein capture devices with the introduction of its new 116mL and 232mL GORE® Protein Capture Devices with Protein A. The offerings strengthen Gore’s chromatography device portfolio and follow the commercial availability of its 58mL Protein Capture Device in Q4 of 2021.

Clinical evaluation of PEC-Encap has resumed using sentinels created with the novel membrane; preclinical and initial clinical data suggest the novel membrane can mitigate the foreign body host response.

GORE® STA-PURE Flexible Freeze Containers' patented design was engineered to maximize container strength while the high-purity, biocompatible fluoropolymer composite film was selected for its durability and low extractables profile. The choice of Gore as one of the winners was based on it's potential impact on the industry. Drug manufacturers now have a high purity option for bulk drug storage that won't become brittle and potentially break or leak in use.

Gore is adding to it's range of affinity chromatography devices with the larger 9.0 mL size device for applications in process development, pre-clinical and early clinical drug development. This launch is significant because it demonstrates that this innovative membrane technology can be scaled to larger sizes without losing performance benefits.

Mayo Clinic and W. L. Gore & Associates Inc., a global materials science company, have formed a joint venture to advance the development of implantable cell therapies to treat debilitating conditions with no cure.

W. L. Gore & Associates has introduced the newest member of its family of occluders, the GORE® CARDIOFORM ASD Occluder, which has received CE Mark. The device offers physicians a clinically proven design in a device that, in a recent study, met its primary endpoint for the percutaneous, transcatheter closure of ostium secundum atrial defects (ASDs).

W. L. Gore & Associates announced that GORE® ENFORM Biomaterial for use in abdominal wall reconstruction procedures recently received the Innovative Technology designation from Vizient, Inc., the largest member-driven health care performance improvement company in the U.S.

Gore announces the first U.S. implant of the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System. This first case follows the recent FDA approval for this new device.

W. L. Gore & Associates announced the U.S. Food and Drug Administration’s (FDA’s) premarket approval (PMA) of the GORE® CARDIOFORM ASD Occluder for the percutaneous closure of ostium secundum atrial septal defects (ASDs).